Home > Insider Trading > Filing (0001628280-25-031117)

Filing Details

Accession Number:: 0001628280-25-031117
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-06-12 19:28:32
Reporting Period:: 2025-06-10

Filing Date:: 2025-06-12
Accepted Time:: 2025-06-12 19:28:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588978	Procept Biorobotics Corp	PRCT	Surgical & Medical Instruments & Apparatus (3841)	260199180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1881616	Rohit Antal Desai	C/O Procept Biorobotics Corporation 150 Baytech Drive San Jose CA 95134		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-06-10	4,862	$63.23	84,501	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-10	18,412	$64.02	66,089	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-10	1,726	$64.67	64,363	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Acquisiton	2025-06-10	1,538	$0.00	8,403	No	4	A	Direct
Common Stock	Disposition	2025-06-11	7,788	$62.59	56,575	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-11	11,495	$63.47	45,080	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-11	5,717	$64.27	39,363	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-12	19,951	$61.28	19,412	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2025-06-12	5,049	$62.33	14,363	No	4	S	Indirect	By The 2:22 DNA Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	A	Direct
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-06-10	2,771	$0.00	2,771	$64.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,771		2035-06-09	No	4	A	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on Novemer 5, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.56 to $63.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.56 to $64.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.08 to $63.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.08 to $64.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.08 to $64.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.89 to $61.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.89 to $62.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The Stock Option was granted on June 10, 2025 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.